1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC).
Saved in:
| Title: | 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC). |
|---|---|
| Authors: | Martin Romano, P.1 (AUTHOR), Roubaud, G.2 (AUTHOR), Lavaud, P.3 (AUTHOR), Cabart, M.4 (AUTHOR), Pages, A.5 (AUTHOR), Vasseur, D.6 (AUTHOR), Colomba, E.7 (AUTHOR), Cousin, S.8 (AUTHOR), Toulmonde, M.9 (AUTHOR), Grellety, T.10 (AUTHOR), Castel Ajgal, Z.11 (AUTHOR), Chabanon, R.12 (AUTHOR), Parpaleix, A.13 (AUTHOR), Buzzatti, G.14 (AUTHOR), Fizazi, K.15 (AUTHOR), Gomez-Roca, C.A.16 (AUTHOR), Italiano, A.10 (AUTHOR), Loriot, Y.15 (AUTHOR), Postel-Vinay, S.1 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1334-S1334. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 159078579 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Martin+Romano%2C+P%2E%22">Martin Romano, P.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Roubaud%2C+G%2E%22">Roubaud, G.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lavaud%2C+P%2E%22">Lavaud, P.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cabart%2C+M%2E%22">Cabart, M.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pages%2C+A%2E%22">Pages, A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vasseur%2C+D%2E%22">Vasseur, D.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Colomba%2C+E%2E%22">Colomba, E.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cousin%2C+S%2E%22">Cousin, S.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Toulmonde%2C+M%2E%22">Toulmonde, M.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grellety%2C+T%2E%22">Grellety, T.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Castel+Ajgal%2C+Z%2E%22">Castel Ajgal, Z.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chabanon%2C+R%2E%22">Chabanon, R.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Parpaleix%2C+A%2E%22">Parpaleix, A.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Buzzatti%2C+G%2E%22">Buzzatti, G.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fizazi%2C+K%2E%22">Fizazi, K.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gomez-Roca%2C+C%2EA%2E%22">Gomez-Roca, C.A.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Italiano%2C+A%2E%22">Italiano, A.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Loriot%2C+Y%2E%22">Loriot, Y.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Postel-Vinay%2C+S%2E%22">Postel-Vinay, S.</searchLink><relatesTo>1</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 7, Vol. 33, pS1334-S1334. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=159078579 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.07.1820 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S1334 Titles: – TitleFull: 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Martin Romano, P. – PersonEntity: Name: NameFull: Roubaud, G. – PersonEntity: Name: NameFull: Lavaud, P. – PersonEntity: Name: NameFull: Cabart, M. – PersonEntity: Name: NameFull: Pages, A. – PersonEntity: Name: NameFull: Vasseur, D. – PersonEntity: Name: NameFull: Colomba, E. – PersonEntity: Name: NameFull: Cousin, S. – PersonEntity: Name: NameFull: Toulmonde, M. – PersonEntity: Name: NameFull: Grellety, T. – PersonEntity: Name: NameFull: Castel Ajgal, Z. – PersonEntity: Name: NameFull: Chabanon, R. – PersonEntity: Name: NameFull: Parpaleix, A. – PersonEntity: Name: NameFull: Buzzatti, G. – PersonEntity: Name: NameFull: Fizazi, K. – PersonEntity: Name: NameFull: Gomez-Roca, C.A. – PersonEntity: Name: NameFull: Italiano, A. – PersonEntity: Name: NameFull: Loriot, Y. – PersonEntity: Name: NameFull: Postel-Vinay, S. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2022 Supplement 7 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
